Consensus Estimates and Trading Data for Argos Therapeutics, Inc. (ARGS)

In the past 52-week period, shares of Argos Therapeutics, Inc. (NASDAQ:ARGS) have moved within the range of $0.13 to $5.68. On the stock’s most recent trading day, the company’s shares ended the regular session at $0.17, which is 97.01% higher than its 52-week high.

Argos Therapeutics, Inc. (ARGS) has demonstrated a 20-day simple moving average (SMA) of -4.02%, and a 50-day SMA of -3.01%. This public company’s current market capitalization stands at $14.86 million.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Checking the amount of enthusiasm that Wall Street analysts hold for a particular stock is crucial when thinking about entering a position. According to the latest data, the consensus recommendation for Argos Therapeutics, Inc. (ARGS) is Hold.

Public companies normally post earnings and revenue results that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Argos Therapeutics, Inc. (ARGS) delivered a 46.50% surprise with its net revenue.

Meanwhile, during the same quarter Argos Therapeutics, Inc. (ARGS) delivered a -35.00% earnings surprise. Net earnings for the quarter were posted at -$0.13 per share, whereas Wall Street had forecast -$0.20 per share.

Ownership at Argos Therapeutics, Inc. (ARGS), According to Most Recent SEC Filings

A publicly-traded organization’s latest 13F filings tell us important details about its institutional ownership. Argos Therapeutics, Inc. (ARGS) has 0 billion shares outstanding currently, 18.44% of which belong to institutional investors.

Additionally, according to the most recent 13F filing from Argos Therapeutics, Inc. (ARGS), there were 6 new positions totaling 1,022,441 shares of the company’s stock. There were 12 sold out positions, on the other hand, totaling 412,836 shares.

Short, Medium and Long Term Indicators

Assessing the average trade volume of a public company’s stock in the short, medium and long term is helpful to gain an understanding of trading activity and investor sentiment. Argos Therapeutics, Inc. (ARGS) has had a 20-day average volume of 8,391,335 shares, with an average of 60% of short term indicators pointed at Sell.

The stock’s 50-day average volume has been 5,764,872 shares, with an average of 50% of medium term indicators pointing toward Sell. Finally, its 100-day average volume is 4,288,186 shares with 67% of long-term indicators pointing to Sell.